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I N T R O D U C T I O N 
There is a general agreement that the breast is horraonally 
controlled, however few data exist regarding the mechanism 
of action and interaction of these hormones and the responses 
of breast tissue. Breast may also be a primary endocrine organ 
as suggested by Diamond (1982). It was seen that microarchitecture 
pattern of breast tissue changes in response to hormonal changes 
throughout the menstrual cycle and during the life of the women 
(Vogel et al 1981). Recent evidence suggests that a neuroendocrine 
imbalance is likely cause of benign breast disorders . However 
studies of both steroids and peptide hormones have shown conf-
licting results and no precise hormonal abnormalities has emerged 
so far (Kumar et al 1984). 
Jick et al (1974) suggested that the clinical use of dopamine 
antagonists such as the Rauwolfia drugs and the Phenothazines, 
which leads to an elevation of (PRL) secretion, resulted in 
an increased incidence of breast tumours, but this study was 
contradicted by other (Mack et al 1975, Wagner 1978). 
Later on the involvement of PRL in sustaining the growth 
of experimentally in^duced rat mammary tumours was established 
(Partridge et al 1979). A number of studies of plasma PRL level 
in patients with breast cancer and controls have been performed 
but the results present a mixed picture (Kwa et al 1974, Wang 
et al 1987), may be because of the pulsatile secretion of the 
hormone. 
- 2 -
The importance of PRL receptors as an index of responsive-
ness of the tumour tissue has been established in recent years 
as hormones influence cells by first binding to high affinity 
receptor protein located either on the cell surface or in the 
cell interior. Various studies have been done to locate the PRL 
receptors in benign and malignant tissue of breast . Evaluation 
of the activity of hormone receptors as an index of response 
of treatment with either hormone administration or endocrine 
ablation is clearly of clinical importance. 
This study was designed to examine immunohistochemically 
detectable PRL in various breast lesions using a highly sensitive 
modified version of Dlnitro-phenyl (DNP) hapten sandwich staining 
(DHSS) procedure (Jasani et al 1981) Efforts are in progress 
for biochemical estimation of PRL binding in particulate membrane 
preparation of breast t issue. The other peptide hormones of 
anterior pituitary like LH 8 FSH which have a direct trophic 
action on gonads may also be having a direct relationship to 
breast. Attempts are being made to study the binding of these 
on breast tissue preparations. 
•.• J Ktt •,!< •.*< 0« 
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REVIEW OF L I T E R A T U R E 
2.1 ENDOCRINE CONTROL OF BREAST: 
Although there is a general agreement that the breast 
is hormonally controlled it is not yet known whether human 
breast is purely endocrine target organ or itself secretes hormones 
into the blood, (Kolodny et al 1972). The in vivo hormonal 
studies indicate that mammary tissue regresses following removal 
of the specific endocrine gland, and that the growth can be 
restored and even stimulated in these regressed tissue by supp-
lying the hosts with specific hormones from the same endocrine 
glands. Also none of the hormones, alone or in combination, 
have shown consistently to be growth promoting in vitro for 
unprimed or regressed mammary tissue. 
The major development in the female breast occurs at 
the time of puberty which is characterized by a number of 
endocrine changes (Styne 6 Grumbach 1978). After puberty owing 
to the cycle production of oestrogen by the ovaries, accelerated 
rate of mammary growth take place. Oestrogen is the hormone 
responsible for development of the ductal epithelium whereas 
progesterone is associated with lobular alveolar proliferation. 
Progesterone may also act as an antiestrogen, antagonizing the 
action of oestradiol on duct cells (Vorherr and Messer, 1978) 
by decreasing the concentration of oestrogen receptors (Kuttenn, 
et al 1981). A ratio of oestrogen to progesterone of 1:20 to 
1:100 is considered to be optimal for mammary development. 
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PRL together with the sex steroids promotes growth 
of the ductulolobular alveolar structure. In addition PRL is 
considered to be the significant lactogenic hormone. The endocrine 
control of milk formation by the differential breast is complex 
requiring in addition to appropriate primary by oestrogen and 
progesterone, specific lactogenic hormones and the permissive 
action of glucocorticoid insulin, thyroxine, and in some species 
growth hormones. Thus as endocrine target organ the breast 
has very complex:^ control mechanism (Diamond 1982). 
2.2 PROLACTIN: 
Ovine PRL has been isolated in highly purified form by 
various investigators (white et al 1937, 1942, Li et al 1940a, 
1941, Cole and Li 1955). It is a protein of molecular weight 
23,300 (Li et al 1957) and isoelectric point at PH5.7. It consists 
of a single polypeptide chain (Li 1957) with two tryptophan 
residues and three disulphide bridges (Li 1949), Ovine PRL 
consists of 198 amino acids with threonine at the amino terminus 
and half cysteine at the carboxyl end. Thus it has free amino 
acid group but no free carboxyl terminus. For this reason, 
Li (1949) suggested that the peptide chain has an intrachain 
disulphide bridge forming a ring. The three disulphide bridges 
are found between residues 4 and 11, between residues 190 and 
198 and between 58 and 173. The two tryptophan residues are 
in positions 90 and 149 and seven metheonine residues are in 
position 24, 36, 53, 81, 104, 129 and 131. There are seven 
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tyrosine residues in PRL. One of these tyrosine residues is 
buried as revealed by spectorophotometric titration of the hormones 
in KCL solution (Ma et al 1970). The buried tyrosine becomes 
ionized only after extensive alkali denaturation. However, all 
seven tyrosyl residues were found to react with tetranitrometh^~^ane 
(Ma et al 1970). 
Spectrophotometric titrations and rates of t ryptic digestion 
indicated that nitration of the molecule produced significant 
conformational changes in i t . Apparently the biological and immo-
logical properties of PRL do not depend upon the intergrity 
of tyrosine residues as well as the molecular conformation. No 
bound carbohydrate has been found in PRL. 
Procedures which are satisfactory for the isolation of 
PRL from the pituitaries of other species have not proved effective 
with human pitui tar ies . While fractions possessing PRL activity 
have been obtained, these fractions have all been rich in growth 
hormones. Thus the nature of PRL remains a mystery of current 
pituitary endocriinology. 
PRL is found to have many physiological roles in animals. 
It has a luteotrophic action on the ovary in some species, it 
induces changes in maternal behaviour which are important for 
the helpless young, and it has general metabolic actions in 
the hypophysectomized animals which are unrelated to reproduction. 
Also under suitable experimental conditions PRL has been shown 
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to be calorigenic and diabetogenic as well as to promote protein 
synthesis and to increase the rate of choridroitin sulfate formation 
in cartilage. In most species the PRL content of pituitaries 
from female animals higher then that of male animals. PRL, 
a peptide hormone synthesized in the pitui tary, plays the c r i -
tical role in the initiation as well as maintenance of milk secretion 
if sukling stimulus' is present (Noel et al 1974). 
2.3 CONTROL OF PROLACTIN SECRETION: 
PRL differs from other anterior pituitary hormones in 
that i ts secretion is under predominant toxic inhibition by the 
hypothalamus. Thus any interference, be it surgical or due to 
disease which disrupts hypothalamic/pituitary connections results 
in hyperprolactinaemia. There is a considerable body of data 
supporting the hypothesis that dopamine (DA) is the natural 
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PRL inhibitor factor. The concentration 10 to 10 mole/1 
of DA is required on to the portal capillary bed to inhibit 
the release of PRL from the anterior pituitary gland. Furthermore, 
drugs which inhibits the release of DA into portal blood result 
in enhanced PRL release, whereas the rapeutic agents stimulating 
DA secretion into portal blood results in suppression of PRL 
secretion. 
In man TRH is a potent stimulator of PRL release. Tashjian 
et al (1971) showed that TRH stimulate PRL release in vi t ro . 
Basal PRL level fall following di l ivery, but PRL secretion is 
enhanced by stimulation of breast such as the act of nursing 
(the so called suckling relex) which requires the presence of 
other hormone oxytocin. 
2 . 4 ROLE OF HORMONES IN MAMMARY TUMORIGENESIS: 
Breast undergoes changes throughout the menstrual cycle 
and during the life of women and thus is affected by various 
hormones like oestrogen, progesterone, androgen, growth hormone, 
prolactin, insulin, corticosttoids, gluco-corticoids and thyroxine. 
The reproductive endocrine system which changes during the 
menarche, the menopause and after child bir th may contribute 
considerably to the aetiology and pathogenesis of breast cancer. 
Mammary cancer is not a homogenous entity but it is a heterogenous 
collection of carcinoma of varying biologic potentials and only 
a few consistent hormonal relationships have emerged. There 
is an increase cancer risk with early menarche and late menopause. 
Oophorectomy early in life exerts a protective effect against 
mammary carcinoma as does an early full term pregnancy. In 
some cases there is regression of tumour when treated with 
oestrogen. This establised an id€3a that there may be a significant 
endocrine abnormality in women with breast cancer. 
Sherman et al (1974) put forth a hypothesis attempting 
to provide a pathophysiological interpretation of the various 
endocrine related ri .^, factors of breast diseases as shown in 
table-1. They further indicate that some of these r isk factors 
interact and are not necessarily independent of each other. 
Breast cancer risk factors (Sherman et al 1974) (TABLE-1) 
Increased Decreased No effect 
7 
Late first pregnancy Early first Oral contraceptive 
pregnancy, Lactation Parity 
Nulfeparity, Early castration 
menarche^ Late 
menopause i obesity^ 
low androgen 
excretion. 
Many of the first situation might be associated with abnormal 
ovarian follicular maturation as well as irregular or dificient 
progesterone production by coprus luteum. This would result 
in a hormonal environment of relative oestrogen excess and pro-
gesterone deficiency, a situation theoretically related to the 
development and progagation of breast neoplasia. They hypothesis 
was based on several assumptions and observations. 
(i) Oestrogen, if not itself an inducer of breast cancer are 
important cofactors in the etiology of breast cancer (Mac 
Mohan et al 1973, Cole et al 1978, Nisker and Siiteri 1981). 
(ii) Progesterone is an important inhibitor of oestrogen action 
(Botella-Llusia 1973, Nisker and Siiteri 1981) though it 
also synergizes with the latter to produce the differentiated 
cell population in the breast. 
(iii) Corpus luteum progesterone production is a common conse-
quence of abnormal follicular maturation. It may be mani-
fested as limited progesterone secretion during a luteal 
- 9 -
phase of either normal (inadequate luteal phase or diminished 
(Short luteal phase)length. 
(iv) Prior to the menopause, there is a variable period of 
time during which menstural cycles are irregular in most 
women. (Treloar et al 1967). At this time a period of 
unopposed oestrogenic stimulation of up to 8 years may 
occur. He thus proposed that late menopause might be 
associated with a greater proportions of cycles exhibiting 
progesterone deficiency. 
(v) Like early menarche, a breast cancer r isk factor, might 
be associated with an earlier onset of and longer exposure 
to an environment characterised by oestrogen production 
in the absence of the regular secretion of appropriate 
amounts of progesterone (Mac Mohan et al 1982b). 
(vi) Age at first full term pregnancy is strong determinant 
of the breast cancer r i sk , the earlier the first bir th 
the less is the risk (Wynder et al 1960, Mac Mohan et 
al 1970, 1973, Craig et a l , 1974, Henderson et a l , 1974), 
Drife (1981) has proposed that it occurs because of diffe-
rential responsiveness of breast tissue before and after 
the first full term pregnancy to the protective effects 
of progesterone. He explained this as before a first full 
term pregnancy the breast has few progesterone receptors, 
and therefore, during the normal menstrual cycles the 
breast is stimulated largely by oestrogens. Further, he 
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suggested that a first full term pregnancy somehow results 
in the development of progesterone receptors so that after 
the first b i r th , normal cycles result in adequate stimulation 
of the mammary ductal cells by progesterone cellular diffe-
rentiation and a consequent reduction in r isk of breast 
cancer. The exact role of reproductive endocrine system in 
the development of mammary cancer remains to be clarified. 
2 . 5 . HUMAN PROLACTIN IN BENIGN BREAST DISEASE: 
Several reports on plasma PRL levels in patients with 
various benign breast diseases have been based on single samples 
and the possibility of abnormal profile due to mentioned stages 
and emotional and other conditions can not be excluded. In order 
to avoid these influences, PRL levels have been estimated in 
serum samples taken daily through out the menstural cycle of 
patients with benign breast disease, vwmnen who suffer cyclical mastalgia 
frequently show a slight elevation of serum PRL (Cole et a l , 
1977], Moreover, a significant positive correlation was present 
between age and PRL in cystic breast disease (Cole et al 1977) 
but not in mammary fibroadenosis or normal women. It was also 
found that symptoms of mastalgia can be relieved by inhibiting 
PRL secretion with the dopamine agonist bromocriptine (Mansel 
et al 1978). This result was supported by Kumar et al (1984) 
in which it was found that release of PRL, LH and FSH was 
significantly greater in cyclical mastalgia patients than controls 
and suggested an alteration in lactotroph in these patients. 
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2 . 6 . HUMAN PROLACTIN IN BREAST CANCER: 
Higher plasma PRL levels have been reported in breast 
cancer patients than in healthy controls (Murray et al 1972, 
Rolendi, et al 1974) but this could not be confirmed by other 
studies (Frank et al 1974, Dicky 1972, Boyns, 1973), Sarfaty 
et al (1976) compared plasma PRL levels in women and in patients 
with primary or metastatic breast cancer. Whereas PRL levels 
were generally higher in normal premenopausal women or breast 
cancer patients than in respective post menopausal subjects or 
in women after ovariectomy, within each category breast cancer 
patients had significantly increased PRL values. Following ovari-
ectomy, PRL levels dropped more sharply in responders than 
in non responders to endocrine therapy (Sarfaty et al 1976). 
It has been reported that pituitary PRL varies according 
to age, menstrual stage, drug usage, e t c . , also it fluctuates 
by the time of day and changes in response to emotional conditions. 
Since hormonal differences may become blunted with increasing 
age and/or debelety, increased PRL secretion in older women 
with breast cancer for instance may be marked by normal old 
age related decline of PRL secretion. According to Robyn (1975) 
PRL may favour both development and progression of breast 
carcinoma but evidence for that is s t i l l indirect and rather 
speculative while it has been proposed, even if endogenous 
PRL by itself may not be an etiologic factor, it would in conjunc-
tion with sex steroids contribute to an accelerated malignant 
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mammary growth as indicated in the more fulminant course of 
breast cancer during pregnancy. PRL is known to exert several 
physiologic actions on breast cells (Shiu and Friesen 1980). 
PRL regulates water and electrolyte balance, milk protein synthesis, 
uridine conversion and incorporation into DNA, and breast fatty 
acid synthetase activity. An increased synthesis of oestrogen 
receptor has also been reported. Kim^  and Furth (1977) stated 
emphatically that all mammary cancer risk factors described 
for human subjects and animals points to a role of PRL in mammary 
carcinogenesis albiet it has been suggested that PRL, if associated 
with breast cancer, must do so at normal levels (Wilson 1973). 
2 .7 . HORMONES RECEPTORS: 
The biological effect of hormones is dependent on at least 
two factors, serum concentration of hormones and target tissue 
responsiveness. The protiens or glucoproteins located on or 
in target cells initially bind hormones and then translate the 
hormonal message into hormonal actions. Any change in hormone 
receptors are considered as one determinant of tissue responsive-
ness. Thus these receptors are not only important in carrying 
out physiological regulation of endocrine target cel ls , but are 
also the potential sites of disordered function of the endocrine 
system. Hormone receptors or binding sites have been demonstrated 
in various preparations of human and animal mammary tissue 
for oestrogens (Korenman 6 Dukes 1970, Gardner a Wittliff 1973, 
Hunt 8 Muldoon 1977) and progesterone (Mc Guire 5 Horwitz 1978). 
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Realising the importance of hormones and their effect on mammary 
tumourigenesis, attempts were made by various workers to study 
in detail the hormone profile in BBD patients and breast cancer 
patients, and estimation of hormone receptors and their valve 
have also helped in the treatment of breast disease especially 
in the case of steroid receptors (Calandra et al 1984). 
PRL is one of the principal hormones regulating the alveolar 
function of the mammary gland (Anderson, R.R. 1974, Vorherr, 
H. 1974). PRL first binds to specific receptors located in the 
plasma membrane of the cell . This is the first even in the 
biological action of PRL and other polypeptide hormones on 
the target t issues. Following this binding a number of effects 
within the cell can be observed. These effects include at the 
nuclear level, an activation of the transcription of milk protein-
genes and a stimulation of DNA synthesis. The occurance of a 
specific receptor for PRL was first reported in mouse mammary 
glands by Turkinton (1970). The significance of assay of PRL 
receptor as a quantitative index of the responsiveness of the 
target tissue has been emphasized as monitoring of the receptors 
on mammary tumour cells may have the potential of predicting 
the responses of the cells to prophylasis and therapeutic actions 
of PRL. 
2.7(a) OESTROGEN AND PROGESTERONE RECEPTORS IN HUMAN BREAST: 
The value of determining the presence of oestrogen receptor 
(ER) and progesterone receptor (PR) in predecting clinical r e s -
ponse of breast cancer patients to hormone therapy is well recog-
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nised, various biochemical procedures have been accepted for 
the routine detection of solubilised steroid receptor protein 
in human breast cancer. Histochemical and immunohistologic visua-
lization of steroid hormone binding in human malignant breast 
tissue has also been attempted. (Louis et a l , 1982). An immuno-
histochemical method utilizing polyclonal antibodies to cytoplasmic 
ER and precipitation of cytoplasm processing procedure which 
allows in situ precipitation of cytoplasm ER value were used. 
(Raam et al , 1987). 
Both the quantitative ER levels and the percentage of 
ER positive specimen were directly related to the age of patient. 
As a result of this strong relationship between age and ER, 
specimen from postmenopausal patients had higher ER levels 
than specimen from premenopausal patients. But within individuals 
of the same age, the proportion with receptors appears to be 
unrelated to menopausal status (Thorpe et a l , 1983) suggesting 
that age is a more important determinant of receptor status 
than menopause. However, Bertuzzi et al , (1981) found that 
the proliferative activity of tumours from patients with the 
same menopausal status was higher in ER negative tumours than 
in ER positive tumours. The proliferative activity decreases 
from premenopausal to postmenopause with both ER positive 
and ER negative tumours suggesting that there may be factors 
other than oestrogen inversly related to the patients age that 
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play a determinental role in cell proliferation of breast cancer. 
The relationship between steroid receptors and size of primary 
tumour reveals a tendency that large tumour to be ER negative 
(Holdaways and Mountjoy 1978). Large tumours might have evidence 
of tumour necrosis that could result in a lack of steroid recep-
tors or they may simply be an indication of more aggressive 
disease. 
It might the hypothesized that for patients with large 
tumours the receptor concentration would be higher for node posi-
tive patients than for those with negative nodes. However subse-
quent analysis failed to identify any correlation between nodal 
involvement and receptor concentration even for large tumours. 
These appears to be no relationship with progesterone 
receptor for either age on menopausal status when these variable 
were analysed seperately. But premenopausal women had higher 
progesterone receptor concentration than postmenopausal women 
when patients of the same age were compound, perhaps reflecting 
greater estrogen- mediated synthesis of progesterone receptor. 
(Clark et al 1984). 
2 .7 (b ) PROLACTIN ! RECEPTOR: 
The existence of PRL receptors (PRL-R) in many different 
animal species is supported by extensive evidence. Since more 
than 80 diverse biological activit ies have been reported for 
PRL, it is not surprising that PRL-Rs have been identified in 
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many different organs. In mammals, the mammary gland and the 
gonads are undoubtedly major target organs at which PRL expresses 
i ts biological actions. De-Souza et al (1976) visualized PRL-R 
with immunoperoxidase technique. Later on Purnell et a l , (1982) 
and tihadly and W&lker ,(1983) concluded that immunocytochemistry 
is a suitable method for demonstration of PRL binding sites 
in human breast tissue and provide useful information with regard 
to tumour heterogenesity. 
Partridge and Hannel (1979) reported the examination of 
eight primary human breast carcinomas and one secondary human 
breast carcinoma (Scalp), which revealed evidence for the presence 
of PRL binding s i tes . Later on Peyrat et a l , (1982), Carlo et 
al (1984) Hermite-Baleriaux, et al . . . (1987) and 
various other workers have determined the PRL-R in human 
breast tumours membrane preparations. 
2.7(c) RELATIONSfflP BETWEEN OESTROGEN. PROGESTERONE AND 
PROLACTIN RECEPTORS: 
Some studies indicated that PRL and oestrogen are the 
two hormones implicated in the regulation of mammary gland 
growth. No correlation, has been shown between serum PRL levels 
and these steroid receptors values in breast cancer (Vinka et 
al 1980). Never the less , a recent publication (Ben David 1981) 
reported a higher dependency of breast cancer on PRL than 
on steroid receptor according to their study on binding sites 
PRL (PRL-R). 
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Calandra et al (1984) studied the receptors in breast 
with the aim. 
1. To investigate the receptor status (ER Vs PR in primary 
and metastatic mammary carcinoma. 
2. To correlate the existence of ER/PR with some clinical 
feature. 
3. To assess the interrelationship between ER/PRL-R in some 
tumours. 
4. To established the incidence of these receptors in the 
local population in comparison with what has been published 
by other groups (Mc Guire et al , 1978, Vinko et al , 
1980). They have considered a positive ER(ER+) assay 
for human breast specimen when the number of binding 
site was equal to/on higher than 2 mol/mg protein and 
for PR (PR+) level equal to/or higher 5 mol/mg protein. 
Concentration of oestrogen and progesterone receptors (ER 
PR in cytosol f mol/mg in the group and the comparisfpn between 
pre S post menopausal patient with human breast carcinoma 
was given by them as below :-
TABLE-2 
Whole group 
PAe'yyiencPa.uSul 
ER 
PR 
ER 
PR 
140.3 +/- 11 .1* 
210.2 +/ - 16.3 
(JO.8 + / - 7.3 
190.2 + / - 23.1 
(970)** 
(970) 
168 
168 
TABLE Contd 
- 18 -
Posrme770pauS'a[ ^^ ^^g_2 V - 19.6 802 
PR 203.4 +/- 19.6 802 
* Mean +/- SEM. 
** Number of patients investigated. 
These results agree with the finding of another groups 
and particularly to the higher ER level in post menopausal pat i-
ents. They also studied the incidence of breast tumours containing 
or not PRL-R and found that it is equally distributed (48% Vs. 
52%) and there was a lack of correlation between PRL-R and 
ER. were approximately equally seen in the the presence or 
absence of PRL-R (34% Vs. 42%). Table-3. 
Distribution of prolaction and oestrogen receptors (PRL-R, 
ER) in human breast carcinoma. 
TABLE-
PRL-R + ER + 
PRL-R + ER -
PRL-R - ER + 
PRL-R - ER -
-3 
17/50* 
7/50 
21/50 
5/50 
34% 
14% 
42% 
10% 
* Number of patients investigated. 
2 . 8 . IMMUNOCYTOCHEMICAL METHOD OF LOCALIZATION OF TISSUE 
ANTIGEN: 
The possibili ty of locating specific substances that can 
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not be precisely characterised by special stains would appear 
to be a useful addition to the diagnostic armoury of the Patho-
logists. Immunocytochemistry has been available as an investigative 
tool since the pioneering work of Coons et al (1942) with fluore-
cein labelled antibody. As the name suggests it identifies a 
tissue antigen with reference to morphology by means of a specific 
antigen antibody reaction rendered visible by a suitable marker 
(fluorochrome). With this capacity, this technique has made 
many important contributions to the advancement of both medical 
and biological knowledge. Though immunofluorescent technique 
are the most widely used immunocytochemical method because 
of its speed and simplicity in routine laboratories, yet it is 
now being replaced by new techniques due to certain limitation 
it possesses. It could only be applied to fresh frozen unfixed 
tissue. Formaline paraffin processed material could not be used. 
Further, unstability of fluorescence phenomenon, requirement 
of expensive equipments, for i ts examination, difficulty in quan.-
titation, lack of electron opacity made it necessary to use al ter-
native marker. Avrameas S Uriel (1966) and Nakane and Pierce 
(1966) used enzyme as immunochemical markers to over come 
many of the limitation of fluorescent methods. Further several 
antigens of histological importance, including intracellular immuno-
globulins and hepatit is B antigen were demonstrated in formaline 
paraffin sections by immunoperoxidase method (Burns, et al 
1924, 1975 a , b , c ) . As the name immunohistochemistry suggests, 
the technique is a combination of immunocytochemestry which 
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attaches the tracer or marker to the specific antigen within 
the tissue sections, and standard enzyme histochemistry which 
visualysis the tracer for bright field or electron microscopy. 
Any enzyme that can be detected by a reliable histochemical 
method and that does not modify the structure of the cells , 
can be employed. Most commonly used enzymes are peroxidase, 
glucose oxidase, acid or alkaline phosphatase. Horse raddish 
peroxidise is most commonly used. They have high specific 
activity and are relatively stable at room temperature. The 
antibody is labelled with suitable enzyme and the labelled antibody 
antigen complex was revealed by ordinary light microscopy by 
treating it with 3-3 diaminobe^zidine tetrahydrochloride (DAB) 
and hydrogen peroxide (H„0„) (Graham 8 Karnovsky 1966). The 
brown colour developed at the site of enzyme ac-,tivity was 
stable and could be rendered electron opaue with osmium tetraoxide 
( 0 0 . ) . Thus many of the disadvantages of immunofluorescence 
were removed by using enzyme as tracer. Using this principle 
different method could be followed. 
Direct: Method: (Fig.la) 
In th is , the primary antiserum directed against a particular 
antigen is covalently linked to horse raddish peroxidase by 
chemical conjugation. This HRP reacts with the DAB substrate 
giving a brown colour. Here larger a^^mount of antisera is required 
antibody is directly conjugated with enzyme and often the yield 
is less . (Modesto and Pesce 1971). This is the least sensitive 
method. 
(al Direct ;.'clho(l 
0 
A 
Pero<i(tisc conjuqalcd ralibit 
anii-human gaslrin 
Cjslnn in tissue scclion 
((II Unljliellcd anlihcxly ^ y m e fr.clhoj wilh oeroxitjase-anti-oeroxidasc 
complex (PAP) 
Peroxidase and-peroxidase comolex 
(111 Imlifi'ct Mdliod 
Peroxidase conjufjaled swine anli-rabbit IgG 
Rabbit anti-human gastrin 
Ag j Gastrin in tissue section 
S.vine anli-rabOit ItjC 
Rat;bil anti-tiuman gastrin 
Gastrin in tissue section 
(C) Immunconzvme Brif'c? .Vethod 
,0, P I Hjfscradisn peroudase 
Rjbt.l anli-Horseradish peroxidase 
^taBHH Sviine anti-rabbit IgG 
Rat;b.t anti-human gastrin 
Al l) Gastrin in tissue '.ection 
Fig. I. : Schematic representatioa of the 
various immunoperoxidase methods 
for the localisation of anti-
gens, e.g. gastric (a) direct 
method, (b) indirect method, 
(c) immunoenzyme bridge method 
and (d) PAP method. 
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Indirect Method: (Fig. lb] 
In the indirect method, antigen in tissue section is first 
reacted with i ts unlabelled antibody (e.g. rabbit anti human). 
This antigen antibody complex is then reacted with the second 
antibody which is directed against immunoglobulin of the species 
in which the first antibody is raised. The 2nd antibody is 
labelled with enzyme (Swine antirabbit IgG), and the colour 
is developed with DAB. In this method the sensitivity is increased. 
Also less amount of primary antisera is required and purified 
conjugated antisera against Ig of several species are readily 
available. 
Immunoenzyme Bridge Method: (Fig.lc) 
The immunoenzyme bridge method was introduced by Manson 
(1969). In this method antigen specific primary antibody, raised 
in rabbi t , is applied to the section. In the second s tep, swine 
anti-rabbit IgG is applied in excess. Next antiperoxidase serum, 
raised in rabbit IgG molecule, it will bind to the free site 
of the swine antirabbit IgG antibody. Then the section is incubated 
in a solution containing horseraddish peroxidase and the enzyme 
attached to the specific conbining sites on the antiperoxidase 
antibody. Finally, the bound peroxidase is visualised by the 
reaction of DAB. This method rapidly superceded the techniques 
employing conjugated antisera because in addition to low yield, 
conjugation also produces large aggregates of antibody molecule 
which, if attached to peroxidase causes high background staining. 
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Unlabelled antibody enzyme method using PAP complex: (Fig.Id} 
To over come the inherent difficulty of the above method 
Sternberger et al (1970) introduced the use of a soluble peroxidase 
antiperoxidase complex (PAP) as an enzyme. This stable cyclical 
complex is formed by reacting horse raddish peroxidase and 
hyperimmune rabbit sera containing anti-peroxidase antibodies 
at low pH and withmoderate antigen excess. The first two steps 
of this method are i..dentical to those of the immunoenzyme 
bridge method i . e . rabbit « antigen serum followed by excess 
swine anti-rabbit IgG. In the third step PAP complex is applied. 
The peroxidase component of the complex is then visualised 
by treating it with DAB. This method is more sensitive as well 
as shorter then immunoenzyme bridge method* Further refinements 
of these methods have been made by various workers. 
The two factors which may interfere with the interpretations 
of the result of the immunoperoxidase techniques, are (i) endo-
genous peroxidase activity, and back-ground staining. 
These particularly occur in formalin paraffin sections. 
1. Endogenous Peroxidase Activity: 
This activity occurs in red blood cel ls , granulocytes (espe-
cially eosinophils) and acid haematin. It can be dealt with 
by either of the following methods: 
(a) It could be prestained in a colour other than that of the 
immunoperoxidase stained antigen complex (Robinson and 
Dawson 1975). 
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(b) It could be inhibited or removed prior to immunoperoxidase 
staining by treating the tissue sections with 0.5% H„0„ 
in methanol for 30 minutes (Burns, 1975b) or 3.0% H„0„ 
in water for 3 to 10 minutes (Garvin, Spicer et al 1976) 
also use of periodic acid followed by sodium borohyd-
ride treatment help in blocking endogenous peroxidase 
acitivity .Kruseman et al(1975) "^".JBrown et al (1976) reduced 
endogenous staining of red cells by employing a weak (0.001%) 
concentration of water in the DAB solution. 
2. Background Staining: 
It is due to the uptake of reagents by other tissue compo-
nents besides the antigen under investigation. These may be 
connective tissue fibrinogen in blood vessels and immunoglobulin 
in sera used for staining. Weston 8 Poole (1973) suggested 
that paraffin embedded material have increased background staining 
due to connective tissue whereas over washing in phosphate 
buffers increases this problem (Gervais 1972) in cryostat sections. 
The former may be due to the Fc portions of immunoglobulins 
being attracted to the basic groups present in the collagen fibre 
or due to IgG in intersti t ial fluid binding to collagen during 
formaline paraffin wax processing (Brandtzaeg 1974). This reaction 
could be avoided by using gelatinized s l ides . 
There are several methods for reducing the background 
staining. Exposure to highly diluted first antibody i . e . antibody 
against the antigen in question for 24 to 48 hours at 0°C is 
Brown 
colour 
DAB 
p o l y m e r ' ^ 
nascent) 
DAB 
monomer 
Glucose oxidase 
DNP 
labe l led per-oxidase 
con jugate 
Monoclonal DNP 
Specific bridge Ab 
DNP labelled 
universal 2nd Ab 
^r,^ Prim ary Ab 
A A Antigen 
Fig.2. : Schematic representation of DNP-iocalisation System-
their mode of interaction. 
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helpful. Further addition of a nonimmune serum for example 
from the animal species which has been used for producing 
the secondary antibody regent or ovalbumin or bovine serum 
albumin or human blood group-A absorbed swine serum is often 
employed. 
The Dinitrophenyl (DNP) hapten Sandwich Staining (DHSS) Procedure: 
(Fig.2). 
The procedure was discribed by Jasani et al (1981). In 
this method the primary antibody or the second antibody is 
labelled with a hapten dinitrophenyl. A monoclonal antihapten 
antibody is incorporated as a bridge between the primary antibody 
and the enzyme system used for developing colour. DNP- peroxidase 
is the enzyme used in this method and DNP glucose oxidase 
was used to provide nascent oxygen for the DAB reaction (Jasani 
and William 1985, Jasani et al 1985). This method overcomes 
the limitation of the previous methods (PAP method). Fi rs t ly , 
the background staining was greatly reduced as highly diluted 
primary antibody is used. Further, primary antibody was diluted 
in Bovine serum albumin. Secondly, the selection of unique set 
of species specific reagents namely anti-immunoglobulin bridge 
antibody and peroxidase antiperoxidase enzyme marker. 
M A T E R I A L AND M E T H O D S 
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M A T E R I A L S A ND M E T H O D S 
Pat ients with benign and malignant breas t condi t ions were 
s tudied c l in ica l ly and h i s to log ica l ly . Hundred and seven formalin 
fixed paraffin embedded b reas t les ions both r e t r o s p e c t i v e and 
p rospec t ive were s e l ec t ed . These included 40 carcinoma 41 f ib ro -
adenomas, 59 benign cys t i c d isease and 8 gynaecomastia. Benign 
cys t i c d i seases included duct ec tas ia apocrine metap las ia , lobular 
h y p e r p l a s i a and f ibroadenosis e t c . (Tab le -4 ) . 
TABLE-ij. 
BREAST LESIONS No.of Cases Percentage 
Carcinoma 
Fibroadenoma 
Fibroadenosis 
Apocrine metapls ia 
Duct ec tas ia 
Lactating breas t 
Gynaecomastia 
40 
41 
8 
4 
1 
6 
37.38 
38.31 
7.47 
3.73 
0.93 
4.67 
7.47 
The technique of Jasani et al (1981) was used through 
out the present s t udy . 
Anterior p i t u i t a ry col lected from post mortem room were 
taken for pos i t ive control s tud ie s and lymph node or t hy ro id 
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biopsies were taken for negative control. Rabbit antihuman PRL 
and the secondary detection reagents were obtained from Bio 
Clin Chemical Ltd. Cardiff, U.K. The colouring reagent was 
obtained from SIGMA D-5637. 
Multiple sections of Sum thickness were cut from formalin 
fixed paraffin embedded breast tissue as well as anterior pi tui tary 
and lymph node tissues blocks. These sections were picked 
up on gelatenised slides (15% gelatin solution was smeared as the 
slides and these slides were kept at 40°C overnight for proper 
setting of gelatin). In each case routine haemotoxylin and eosine 
staining was carried out along with immunocytochemical method 
for localization of PRL hormone binding site in several batches. 
Each batch included a section of pituitary and a section of 
lymph node or thyroid. 
Dewaxing Procedure: 
Reagents Time 
Xylol 1 2-4 minutes at RT. 
Xylol 2 " 
Xylol 3 
Xylol 4 
Alcohol 1 " 
Alcohol 2 " 
Haemotoxylin Eosin Staining Technique: 
1. Deparaffinised sections were washed in water. 
2. Sections were stained in a solution of hemotoxylin for 
2 to 5 minutes. 
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3. Washed in water t i l l the section is blueing. 
4. Decolourised with a solution of acidic alcohol 1% t i l l the 
cytoplasmic staining by hematoxylin is removed. 
5. Washed in running tap water for 5 to 15 minutes. 
6. Counter stained in 1% aqueous eosin for 1 minute. 
7. Washed rapidly in water and blotted. 
8. Dehydrated in several changes of absolute alcohol. 
9. Cleared in Xylol and mounted in Canada Balsam. 
Immunocytochemical Staining Tectinique: 
1. Inhibition of Endogenous Peroxidase: 
For this purpose pre-incubation of sections was done in 
absolute alcohol containing hydrogen peroxidase. The slides 
were immersed into a mixture of 47.2ml of absolute ethanol 
and 0.8ml of 33% hydrogen peroxidase for 30 minute at room 
temperature (Streefkerk 1972). 
2. Rehydration: 
Slides were washed by immersing these into dist i l led 
water for 2 minute x 3 changes. 
Slides washed by immersing in phosphate buffered saline 
(PBS), pH = 7.1 (O.OIM) for 2 minute x 3 changes. 
After this (DNP) dinitrophenyl localization system was 
used for detection of primary antigenic s i tes . It represent a 
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novel, versat i le , indirect immunoperoxidase bridge technique 
designed for the detection unlabelled primary rabbit or mouse 
antibodies reacted with Ag present in paraffin section. 
3. Incubation with primary antibody {Rabbit antihuman PRL): 
The primary antibody was applied at the dilution of 1:150,00. 
(Dilution profile experiment was carried out to evaluate the 
appropriate dilution. The effectiveness of a-PRL was checked 
by double immunodiffusion against serum of pregnant or lactating 
women). The dilution was done either in Bovime serum albumin 
or normal rabbit serum. The slides were covered with this 
antibody and left overnight incubated at A°C in a closed moistened 
box. 
4. Washing in phosphate buffer saline was conducted by total 
immersion of the slides in a coplin jar (1 min x 3 changes). 
5. Incubation with second antibody labelled with DNP was 
for 30 minutes i . e . antibrabbit Ig G labelled with DNP. 
6. V\/ashing in PBS (1 minute x 3 changes). 
7. Incubation in Ig M anti-DNP bridge antibody (50 to lOOul 
was done for 30 minutes. 
8. Vi/ashing in PBS (1 minute x 3 changes). 
9. Incubation in DNP peroxidase conjugate for 30 minute (50 to 
lOOul). 
10. Washing in PBS (1 minute x 3 changes). 
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11. Incubation in DNP glucose oxidase for generation of nacent 
oxygen (50ul to lOOul) for 30 minutes. 
12. Washing in PBS (1 minute x changes). 
13. Incubation in diamino benzidine (DAB) + glucose + PBS 
(O.IM) in a coplin jar overnight at room temperature in a dark 
place. 
14. Washing distil led water for 1 minute x 3 changes. 
15. Slides were immersed in 1% acetic acid for 1 minute. 
16. Counter staining was done as usual i . e . slides were covered 
with Mayer's Haemtoxylin for 30-45 seconds. Blueing in running 
tap water was done for 5 minutes. Finally sections were dehydra-
ted and mounted in Canada Balsam and studied under a microscope. 
Control Studies: 
1. Sections from postmortem anterior pituitary were used 
as positive control. 
2. Sections from lyraphnode or thyroid were used as negative 
control. 
3. Control slides included omission of a PRL and its substitution 
with the approxpriate dilution of BSA. 
Using above method, staining was done in batch including 
6-8 breast slides lesion and control s l ides . 
R E S U L T S 
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R E S U L T S 
One hundred and seven formalin fixed paraffin embedded 
breast tissue sections were stained by immunocytochemical method 
for localisation of PRL hormone receptor sites in benign and 
malignant breast lesion. All malignant lesions were carcinomas 
TABLE-J 
IMMUNOCYTOCHEMICAL REACTIONS IN BREAST LESIONS 
SI. 
No. 
1. 
2. 
3. 
BREAST LESIONS • 
Carcinoma 
Benign breas t 
d i sease 
Fibroadenoma 
Lactating b reas t 
Apocrine metaplasia 
Fibroadenosis 
Dust ec tas ia 
Gynaecomastia 
IMMUNOCYTOCHEMICAL 
Posit ive 
No. 
33/40 
34/59 
23/42 
5/5 
4/4 
3/8 
1/1 
1/8 
% 
(82 
(57 
(57 
(10 
(10 
(37 
(IC 
(12 
;.5) 
' .6) 
') 
10) 
10) 
.5) 
10) 
:.5) 
FINDINGS 
Negative 
No. 
7/40 
25/59 
25/41 
-
-
5/8 
-
7/8 
% 
(17, 
(42. 
(42. 
-
-
(62. 
-
(87, 
.5) 
.4) 
.4) 
.5) 
.3) 
of various histological grades. Majority (82.5%) of the breast 
carcinoma sections (33/40) revealed positive staining of variable 
intensity (Fig.3). Amongst the benign lesions majority were 
^ ^ ^ ^ .3--
F i g . 3 : Infiltrating carcinoma breast showing positive 
staining for PRL of variable intensity (Immunocyto-
chemistry x 350). 
Fig .4 . : Benigh Breast Tissue section- Epithelial cell lining 
duct showing positive reaction for PRL (Immunocyto-
chemistry x 350). 
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fibroadenomas of which 57% of cases (23/41) showed positive 
staining. Sections of other benign diseases of breast such as 
fibroadenosis, duct ectasia, gynaecomastia were also studied 
(Table-5). 
Further, it was observed that there was a definite relationship 
between the age of the patient and intensity of positive immuno-
cytochemical staining reaction. Majority of the breast carcinoma 
slides showed positive reaction in tumours removed from ladies 
TABLE-^ 
RELATIONSHIP OF IMMUNOCYTOCHEMICAL REACTION WITH 
AGE OF THE PATIENTS 
LESIONS AGE GROU 
{in years) 
_POSITIVE_ 
No. % 
N_EGATiyE_ 
No. % 
Carcinoma -C 30 
31-40 
41-50 
51-60 
> 6 0 
Fibroednoma < . 30 
31-41 
41-50 
2/3 
6/9 
14/16 
5/6 
6/6 
(66.66) 
(66.66) 
(92.5) 
(83.3) 
(100) 
1/3 
3/9 
2/16 
1/6 
-
(33.33) 
(33.33) 
(7.5) 
(16.7) 
-
10/21 (47.61) 
12/17 (70.58) 
1/3 (33.33) 
11/21 (52.39) 
5/17 (29.42) 
2/3 (66.66) 
Fig.5.: Section of breast showing cyst lined by apocrine 
metaplasia [H.E. x 350). 
Fi8-6, 
- ™ - s e ? e i ? „ r ; ^ « , - ? ™ - 3 0 ^ ^ ° ' -
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between the age of 41 to 60 years i . e . in the periminopausal 
patients whereas the tumours removed from ladies in younger 
age i . e . during the active reproductive phase of life, the inten-
sity of staining reaction was poor or irregular (Table-^). 
Epithelial cell lining of both ducts and acini showed posi-
tive staining reaction (Fig.4-). The distribution of reaction varied 
in different individual cases. In some the staining was consistent 
in all ducts and lobule throughout the section examined whereas 
in others there was a variation in intensity of staining reaction 
between ducts and then associated lobules. Amongst the benign 
cystic disease of the breast the cyst lined by apocrine meta-
plastic lesions showing papilliomatosis and epitheliosis were 
strongly positive (Fig. 6^^4>) whereas other benign lesions such 
as duct ectasia, adenosis, fibroadenosis were weakly or hetero-
genously posit ive. 
Gynaecomastia were mostly negatively stained. Only 1 out 
of 8 sections was weakly posit ive. 
Background staining of the breast parenchyma and collagen 
was not prominent in the majority of the cases though weak 
nonspecific staining at the periphery of the sections was a commonly 
observed phenomenon and was ruled out as an edge or a drying 
artefact. 
Positive reaction for PRL was seen in all instances with 
sections of anterior pituitary but there was no evidence of PRL 
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binding in lymph node or thyroid section. These two tissues 
thus acted as positive and negative controls respectively in 
the present study. Out of total number of forty cases of carcinoma 
breast only six (15%) cases did not show any immunocytochemical 
reaction in sections. Rest of the cases revealed a variable reac-
tion, varying from weakly positive to strongly posi t ive. 
TABLE- 7 
IMMUNOCYTOCHEMICAL REACTION IN DIFFERENT HISTOLOGICAL 
TYPE OF BREAST CARCINOMA 
DIFFERENT HISTOLOGICAL NO. OF 
TYPES OF CARCINOMAS CASES 
IMMUNOCYTOCHEMICAL REAC-
TION_ 
Weak Moderate Strong Negative 
Wall d i f ferent ia ted 19 
Poorly di f ferent ia ted 2 
Pap i l l a ry adenocarcinoma 3 
Lobular carcinoma 6 
Carcinoma associa ted 2 
with Page t ' s d i sease 
Metastising into 8 
lymph node 
7(36.8) 5(26.3) 6(31.5) 1 ( . 5 ) 
1(50%) 1(50%) -
1(33) - - 2(66%) 
1(16.66%) 2(33.33%) - 3(50%) 
2(100) - - -
5(62.5%) 3(38%) -
TOTAL 40 11(27.5%) 13(32.5%) 10(25%) 6(15%) 
On fur ther ana lys is of grade of malignancy in re la t ion 
to in tens i ty of immunocytochemical s taining r evea led tha t the 
Fig.8.: Section of fibroadenoma (H.E. x 350) 
P'ig,9.: Positive staining reaction for PRL of the above 
section [Immunocytochemistry x 350). 
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pituitary sections and positively stained breast tissue studies 
whereas concentrated a-PRL increases background staining. The 
optimal staining reaction was obtained at the dilution of 1:150,00 
of a PRL diluted in BSA. 
*r 
Fig.10: Lobular hyperplasia showing positive reaction 
for PRL (Immunocytochemistry x 350). 
D I S C U S S I O N 
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D I S C U S S I O N 
This study has indicated fairly consistant presence of 
immunohistochemical binding of PRL in both malignant and benign 
breast t issues. Sections of more than 5 years old paraffin 
blocks of formalin fixed, breast tissues could be stained as 
we have employed a novel and a highly sensitive method of 
iramunohistochemically localising the PRL binding s i tes . The 
application of immunohistochemistry to the detection of PRL 
binding sites in human breast tumours is potentially of great 
interest. Indeed a tumour may consists of a mixture of positive 
and negative cel ls . Since the radioreceptor assay requires 
tissue homogenization, this technique is not able to distinguish 
between positive and negative cel ls . On the contrary, this 
is theoretically possible by immunocytochemistry. 
De-Souza et al (1976) were the first to claim that PRL-R 
could be visualized with the immuno-peroxidase technique. Then 
Dhadly and Walker (1983) using purified human prolactin and 
a specific antiserum to human PRL, following peroxidase anti-
peroxidase method, were able to detect PRL binding in benign 
and malignant human breast tissue. All these workers have 
used fresh frozen material and found this to be essential for 
immunohistological staining. In this present study, PRL binding 
sites have been detected by immunohistochemistry in human 
benign breast tissue and breast carcinomas. Our success with 
formalin fixed, paraffin embedded tissue is contrary to these 
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previous reports , may be because we have followed a novel 
c 
and a sensitive method of immunoperxidase labelling. Earlier 
/> 
Purnell et al (1982) were able to demonstrate cytoplasmic PRL 
binding in paraffin embedded tissue but had used antiserum 
against bovine PRL while we have used anti-serum against human 
PRL. 
The dilution of anti-PRL required for staining was 100 
times greater in the present study as compared to others (Salih 
et al 1972). The second antibody heavily substituted with 
hapten have proved effective in localising hormones binding 
s i tes , the number of which in tissue may be very low. The 
hapten dinitrophenyl (DNP) reacts efficiently with immunoglobulins 
without altering its capacity to bind antigen. Further use of 
monoclonal IgM type of immunoglobulin as bridge antibody results 
in higher staining sensit ivity. The dilution fraction can be 
increased and thus small amount of primary antibody is required. 
Background staining i . e . uptake of the immunoreagents 
by other tissue components besides the antigen under investi-
gation makes it difficult to interpret the results of the immuno-
peroxidase technique. There are several methods for reducing 
this back ground staining (Ternyanck 1976, Reading 1977). 
We have followed the method of Burns (1975b ) in which 
addition of bovine serum albumin reduces background staining. 
Further exposure to highly diluted anti-PRL overnight at 4°C 
is helpful in reducing the background staining. 
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In the present work while studying the immunohistocheinical 
reaction in the breast tissue it was observed that the breast 
tissue responds to the staining reaction differently. Meaning 
thereby that while multiple sections from the same breast 
were examined, some part of the tissue including the normal 
gave positive reaction, while other parts were negative. Not 
only that even the intensity of staining was variable in the 
same tissue. This type of heterogene, ity in the staining reaction 
was constantly seen in all the lesions including benign, malignants 
and non-neoplastic. Same has been the experience of other 
workers [Purnell et al 1982, Dhadly a Walker 1983). 
A higher incidence (82.5%) of PRL binding in breast 
carcinoma was observed in the present study as compared to 
the previous ones (56%). (Purunell et al , 1982, Dhadly and 
Walker 1983), may be due to more sensitive technique that 
we have used throughout this study. The result of PRL obtained 
by us may be encouraging and this may prove an useful method 
for screening PRL- growth hormone dependent breast tumours 
PRL is one of the principal hormones regulating the alveolar 
function of the mammary gland (Anerson R.R. 1974), The role 
of PRL is implicated in mammary tumorigenesis of experimental 
animals (Welsch C.W. and Nagasawa H. 1977). Further more, 
there is growing evidence that PRL may also be involved in 
the development and progression of some human breast cancers 
(Wilson et al , 1980, Teyssot et al 1981, Shiu P.C. and Iwascow 
B.M. 1985). •. the PRL dependency of mammary carcinoma 
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in women is not yet well understood as the interpretation of 
plasma PRL levels are difficult because of the marked variation 
and pulsatility of its secretion. 
The importance of PRL in human breast cancer is stressed 
as women at increased r isk of the disease because of a late 
age first baby, late menopause, nuUtiparity, obesity, or a 
family history of breast cancer have raised blood levels of 
the hormones (Kwa et al, 1976, 1978, 1981, Wang et al 1986). 
We have found immunocytochemically that majority of the breast 
carcinoma slides show positive reaction of the patients above 
the age of 41 years (Table-6 ). The findings of PRL presence 
in greater proportion in perimenopausal breast cancer tissue 
is of significance as this is in consonance with the presence 
of oestrogen receptor in breast cancer. Sherman S Korenman 
(1974) have hypothesized that unopposed oestrogenic action 
in the perimenopausal period (Say 0 to 8 bears before menopause) 
due to defective progesterone production is a key determinant 
of subsequent r i sk . The unopposed oestrogen is due to defective 
luteal phases m the menopause approaches. Kwa et al (1978) 
observed that post menopausal patients who subsequently develop 
breast cancer have raised plasma PRL levels upto 5 years 
before the clinical diagnosis of disease is made. This could 
suggest incidence of higher positivity of PRL binding of per i -
and post menopausal patients in our study. However Partridge 
and Hannel (1979) who examined nine cases of human breast 
40 
carcinoma have found that specific binding of PRL was occuring 
in at least three of the nine specimen examined. These "prolactin 
receptor positive" tumours were all from premenopausal patients. 
Thus no definite opinion could be made out with regard to 
menopausal status. 
Earlier the decision as to whether endocrine treatment 
is likely to benifit patients with metastatic breast cancer 
was most frequently made on the basis of estimation of estrogen 
receptors in the tumours. However, this dependency of carcinoma 
on oestrogen receptors seems incomplete, as lack of oestrogen 
receptors indicates l i t t le likelihood of beneficial effects from 
endocrine treatment. Also the patients with an oestrogen receptor 
positive tumour has only a 55-60% chance of benefitting from 
endocrine therapy. Thus recent research indicates the significance 
of additional factors such as different hormones in estimating 
more accurately the tumours endocrine responsiveness stressed 
the importance of the search for PRL's role in human breast 
cancer. Since oestrogens are well known to stimulate PRL secretion 
(Shull 6 Gorshi 1984, William et al 1985) it could be stated 
that oestrogen and PRL may interact in promoting mammary 
tumorigenesis (Ben-David 1980). Ben David (1981) in their 
further studies on binding sites for PRL (PRL-R) reported 
a higher dependency of breast cancer on PRL than on steroid 
receptors. 
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The multiple hormonal interactions that take place in 
the normal growth and development of the breast has been 
reviewed by Topper and Freeman (1980). It would, therefore, 
be illogical, at least theoretically, to implicate any single 
hormonal abnormality as a prime factor in the aetiology of 
breast disease. Recently women with BBD have shown to exhibits 
an increased PRL response to TRH or doperidone provocation 
tests (Kumar et al , 1984). PRL binding was detected in 57.6% 
of BBD, similar to that obtained by Kumar et al (1987). These 
findings are contradictory to the observation made by Dhadly 
and Walker (1983) who reported positive reaction in all the 
benign breast lesions. However, no staining was obtained in 
any of the benign breast lesions by De-Souza et al 1979). 
Carlo et al (1984) also rep orted presence and biochemical 
characterization of PRL-R in human benign breast tumours. 
The experience of various workers varied in the field 
of immunocytochemical staining of sections of fibroadenomas. 
In the present study in a good percentage of cases (57) there 
was positive reaction whereas other workers could not demonstrate 
the PRL binding s i tes . It was because perhaps we used a modi-
fied, more sensitive technique for demonstration of the receptors . 
The role of PRL in the overall causation of benign breast patho-
logy is uncertain. The determination and the level of specific 
PRL binding sites in abnormal breast tissue may therefore 
be useful in better understanding of the pathophysiology of 
benign breast disease. 
42 
In the present study the slides showing apocrine metaplasia 
exhibited intense staining. This fact is also shown by Kumar 
et al (1987). He further stated that addition of exogenous 
PRL onto the sections led to considerable selective enhancement 
of anti PRL mediated staining of the apocrine metaplasia cells 
which may indicate that the cells are involved in the production 
of PRL- specific binding s i tes , probably PRL receptors. If 
so, this could suggest a target function on the part of metaplasic 
cells for PRL. Further apocrine metaplasia or pink cell change, 
characterised by high cylindrical cells with granular eosino-
philic cytoplasm projecting as 'Snouts' into the lumen of the 
ducts and cysts has long been regarded of no significance in 
cancer r i sk . Similarly, breast carcinoma originating from apocrine 
metaplasia was considered very rare by Footi 8 Steward (1945). 
On the other hand. Page et al in 1978 reported that patients 
whose initial biopsy have shown apocrine metaplasia may have 
an increased cancer r i sk . Later on Haagenson (1986) also suppor-
ted this observation. He also observed quite higher incidence 
of apocrine type of breast carcinoma, probably arising in meta-
plastic breast t issue. It is possible that the PRL positive 
breast cancer cells seen in the present study may represent 
cells depicting apocrine type breast carcinoma. 
It is interesting to note that the histopathological diffe-
rentiation of breast tumours has got direct relationship with 
the presence of PRL- binding receptors in the study as it was 
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observed that well differentiated tumours has less intense 
reaction to immunocytochemical stain, as opposed to that of 
Dhadly and Walker (1983) who reported the presence of more 
PRL binding sites in well differentiated carcinoma. Also in 
our study metastasing tumours showed stronger reaction to PRL 
immunocytochemical staining. This observation is in correlation 
with the work of Wang et al (1986) in which they identified 
subgroups of patients in which either preoperative and/or 
postoperative PRL levels were significantly correlates to survival 
in all cases, the least favourable prognosis was associated 
with the highest PRL levels . This general trend has been 
confirmed by Dowsell et al (198^ in advanced disease as well 
as in early disease (Dowselt et al 1987) and also by Holtkamp 
et al (1984). Hovrever Bonneterre et al (1987) while studying 
the prognostic significance of PRL receptors in human breast 
cancer have stated that relapse free survival was higher in 
patients with node metastasis. Thus n o . definite conclusion 
Cou^ l^ci be made with regard to PRL incidence and metastasing 
tumours. The hypothesis that PRL might support the growth 
of breast cancer in vivo is indeed supported by invitro exper i -
ments, as shorn-]. ' -_ ' by Peyrat et al (1982) and 
also by other workers (Carlo et al 1979, Partridge et a l , 
1979). These workers have reported that some human breast 
tumours contain low but measurable levels of free PRL receptors 
and this low level of receptors in human breast cancer biopsies 
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does not rule out an important role of PRL in the development 
of tumour. 
All these indicate that PRL might be significant in the 
support of breast cancer growth in vivo and/or conversely 
that hyperprolactinaemia might be only a consequence, by an 
unknown mechanism of the progression of the disease. It may 
be stated that either an unknown factor is secreted which 
acts at the hypothalmo pituitary level to enhance PRL secretion, 
or perhaps that the tumour itself secretes PRL. 
C O N C L U S I O N S 
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From this study following conclusion were drawn. 
PRL binding sites could be detected in human breast tissue 
by immunocytochemistry. Formalin fixed paraffin embedded, 
upto five years or more old breast blocks tissue section have 
shown satisfactory staining for PRL binding s i te . Both benign and 
malignant breast tissue slices have shown variable degree of 
posifivg. staining for PRL binding s i te . The breast carcinoma 
tissue slices have shown more consistent immunostain as compared 
to fibroadenoma tissue. Since the PRL binding sites were more 
commonly seen in carcinoma breast tissue one can not exclude 
the possibili ty of the role of PRL in mammary tumorigenesis. 
Further finding of PRL binding sites presence in greater proportion 
in perimenopausal breast cancer patients is of significance, since 
this is in consonance with the presence of oestrogen receptor 
in breast cancer. 
Apocrine change in epithelial lining had specific PRL bin-
1.72 
ding s i tes . This finding may suggest a role of PRL the aetiology 
of breast cancer through the induction of apocrine change since 
it has recently been shown to be associated with an Increased 
r isk of breast cancer. 
In view of these findings, staining with PRL antibody 
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may prove to be a useful marker for determining of high r isk 
benign breast disease biopsies and immunohistochemical staining 
for PRL may be useful in identifying apocrine type of breast 
carcinoma. 
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